Indegene Limited

rs,

INDGN/SE/2024-25/94 January 30, 2025 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 Dear Sir / Madam, National Stock Exc

56%

nsultancy services across value chain Regulatory submissions Risk management Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solution

12%

egulatory submissions Risk management Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analyt

28%

nagement Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegen

4%

terprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegene. All rights reserved. (1) Revenu

rs1

Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegene. All rights reserved. (1) Revenue contribut

14%

r TAM Lifesciences at Inflection Point We Offer Solutions Across Life Sciences End Markets ~9-14% CAGR (2022-2026) in Outsourcing Operations Across Verticals Patent Cliff Large number of drugs a

93.7%

efficiency and strategy by large biopharma for commercialization of existing pipeline Biopharma 93.7%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) I

2.6%

by large biopharma for commercialization of existing pipeline Biopharma 93.7%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) Indicates revenue contribu

2.5%

mmercialization of existing pipeline Biopharma 93.7%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) Indicates revenue contribution by customer industry

1.2%

ll rights reserved. (1) Indicates revenue contribution by customer industry for Q3FY25. Remaining 1.2% from other industry. 5 Management Commentary on Q3FY25 results Manish Gupta Chairman and Chief

4.9%

stable and profitable growth, and our Q3FY25 numbers reflect this. We achieved revenue growth of 4.9% QoQ driven by continued traction with large pharma customers and growth momentum with mid-size pha

People Business Consulting

2

Notes

1

People Business Consulting

Top 100 Great Managers in India © 2025 Indegene. All rights reserved. 17 Thank You! www.indegene.com Consolidated Financial Data - Third Quarter, Fiscal 2025 Fact Sheet Operational & Financial Metrics Key performance indicators (in INR Mn) Particulars Active clients(1)(No.) Revenue from operations Revenue from operations ($ Mn) YoY revenue growth (2) (%) EBITDA (3) EBITDA margin (%) Profit after tax Profit margin (%) SI. No. 1. 2. 3. 4. 5. 6. 7. 8.

Notes

Quarter ended Growth Dec 31, 2024 Sept 30, 2024 Dec 31, 2023 YoY QoQ 75 7,204 85.2 7.0% 1,501 68 6,868 82.0 8.0% 1,267 20.8% 18.4% 917 1,097 15.2% 65 6,734 80.9 10.3% 1,499 22.3% 988 7.0% 5.3% 4.9% 4.0% 0.1% 18.5% 11.1% 19.6% 13.4% 14.7% 1. 2. 3. Active clients are clients from whom the Company have earned $0.25 million or more in revenues for the last twelve months preceding the relevant date. Based on INR revenue. YoY growth for quarter Dec 31, 2023, based on unaudited financials. Earnings before interest, taxes, depreciation and amortization (“EBITDA”) represents profit/(loss) for the period before income tax expense, finance costs, depreciation and amortization expense, interest income and any exceptional items. Revenue by service offering (in %) Particulars Enterprise Medical Solutions Enterprise Commercial Solutions Omnichannel Activation Others Total Quarter ended (contribution) Growth Dec 31, 2024 Sept 30, 2024 Dec 31, 2023 28.5 55.6 12.4 3.5 28.8 56.2 11.6 3.4 22.6 57.9 13.7 5